GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of small win: SURMOUNT stopped being a problem at week 65 — 52 comments in the full submission. View in context.
1.8k
c/trialwatch·submitted 5 months ago by u/joaquin_stanescu

small win: SURMOUNT stopped being a problem at week 65

Trial Databranch of 11 comments

Right, the SURMOUNT question again, but with numbers this time. I have 5 data points over 6 weeks. The pattern is consistent enough that I do not think it is chance, and boring enough that nobody is going to screenshot it, which is usually a good sign. The thing I would flag for anyone new: the effect I am describing…

Read the full submission and all 52 comments →

This branch

11 comments, started 5 months ago
u/rina_sobczak52 points·5 months ago

STEP, SURMOUNT, SURPASS, SELECT, FLOW, TRIUMPH — read the appendix

replysharereportpermalink
u/annika_fonseca33 points·5 months ago

I am going to push back on this slightly.

replysharereportpermalink
u/curious_panel_only22 points·5 months ago

STEP, SURMOUNT, SURPASS, SELECT, FLOW, TRIUMPH — read the appendix

replysharereportpermalink
u/renal_outcomes_rnephro-curious12 points·5 months ago

the discontinuation arms are the interesting part, not the STEP endpoints

replysharereportpermalink
u/pancreatitis_scare6 points·5 months ago

give the trial name, phase, n, and primary endpoint in the body

replysharereportpermalink
u/paper_trail_paulavetting-15 points·5 months ago

STEP, SURMOUNT, SURPASS, SELECT, FLOW, TRIUMPH — read the appendix

replysharereportpermalink
u/joaquin_stanescuOP1 point·5 months ago

Yeah, absolute numbers matter more than the press release.

replysharereportpermalink
u/nordic_pricing0 points·5 months ago

dropout handling matters, especially on GI-heavy populations

replysharereportpermalink
u/hsa_math1 point·5 months ago

Strongly agree. Phase 2 is investigational, not conclusive.

replysharereportpermalink
u/zaid_roos1 point·5 months ago

give the trial name, phase, n, and primary endpoint in the body

replysharereportpermalink
load more comments (1) →

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →